Protalix Cost Of Revenue vs Ebitda Analysis

PLX Stock

USD 1.14 0.06 5.00%

Protalix Biotherapeutics financial indicator trend analysis is much more than just breaking down Protalix Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protalix Biotherapeutics is a good investment. Please check the relationship between Protalix Biotherapeutics Cost Of Revenue and its Ebitda accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Cost Of Revenue vs Ebitda

Cost Of Revenue vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protalix Biotherapeutics Cost Of Revenue account and Ebitda. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Protalix Biotherapeutics' Cost Of Revenue and Ebitda is 0.53. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Ebitda in the same time period over historical financial statements of Protalix Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Protalix Biotherapeutics' Cost Of Revenue and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Protalix Biotherapeutics are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Cost Of Revenue i.e., Protalix Biotherapeutics' Cost Of Revenue and Ebitda go up and down completely randomly.

Correlation Coefficient

0.53

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Protalix Biotherapeutics income statement and represents the costs associated with goods and services Protalix Biotherapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Ebitda

Most indicators from Protalix Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Tax Provision is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 24.9 M in 2024, despite the fact that Selling General Administrative is likely to grow to (24.2 M).

	2021	2022	2023	2024 (projected)
Total Revenue	38.4M	47.6M	65.5M	68.8M
Depreciation And Amortization	401K	2.2M	1.2M	1.7M

Total Revenue Depreciation And Amortization

Protalix Biotherapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Net Debt	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Non Currrent Assets Other	Common Stock Total Equity	Other Stockholder Equity	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Other Assets	Other Liab
Total Assets		0.03	0.19	-0.24	0.85	0.57	0.95	-0.03	0.0	0.45	-0.61	0.62	0.99	0.6	0.04	0.46	-0.22	-0.16	0.5	0.41	0.51	0.56	0.09	0.02	0.38	0.23
Other Current Liab	0.03		0.43	0.16	-0.24	0.32	-0.14	0.53	0.54	-0.3	-0.27	-0.05	-0.02	-0.02	0.17	0.33	-0.43	0.1	-0.45	0.3	0.2	-0.39	0.13	0.52	-0.29	-0.13
Total Current Liabilities	0.19	0.43		0.56	-0.1	0.19	0.09	0.05	0.39	-0.43	-0.46	0.16	0.18	0.32	0.02	0.13	-0.56	-0.2	-0.1	0.35	0.66	-0.08	0.15	0.42	-0.27	-0.35
Net Debt	-0.24	0.16	0.56		-0.38	-0.36	-0.29	0.13	0.15	-0.19	-0.36	0.14	-0.19	-0.05	-0.35	-0.44	-0.45	-0.31	-0.3	0.32	0.24	-0.31	-0.1	0.15	-0.08	-0.58
Cash	0.85	-0.24	-0.1	-0.38		0.34	0.95	-0.32	-0.31	0.63	-0.37	0.62	0.87	0.66	-0.05	0.31	0.15	-0.12	0.69	0.15	0.38	0.66	-0.05	-0.27	0.56	0.34
Non Current Assets Total	0.57	0.32	0.19	-0.36	0.34		0.41	0.42	0.05	0.31	-0.27	0.46	0.43	0.62	-0.11	0.97	-0.25	0.47	0.18	0.22	0.11	0.22	0.67	0.01	0.2	0.6
Cash And Short Term Investments	0.95	-0.14	0.09	-0.29	0.95	0.41		-0.27	-0.16	0.5	-0.46	0.6	0.96	0.65	0.05	0.34	0.02	-0.18	0.62	0.26	0.54	0.63	-0.04	-0.14	0.39	0.24
Net Receivables	-0.03	0.53	0.05	0.13	-0.32	0.42	-0.27		0.46	0.04	-0.32	0.07	-0.12	-0.08	-0.11	0.36	-0.62	0.36	-0.13	0.39	-0.36	-0.02	0.54	0.22	0.03	0.11
Common Stock Shares Outstanding	0.0	0.54	0.39	0.15	-0.31	0.05	-0.16	0.46		-0.57	-0.42	-0.37	0.0	-0.33	0.61	0.04	-0.7	-0.25	-0.33	0.65	0.02	-0.2	-0.04	0.72	-0.5	-0.49
Non Current Liabilities Total	0.45	-0.3	-0.43	-0.19	0.63	0.31	0.5	0.04	-0.57		-0.21	0.82	0.43	0.48	-0.68	0.27	0.11	0.11	0.55	0.02	-0.08	0.49	0.19	-0.51	0.78	0.69
Other Current Assets	-0.61	-0.27	-0.46	-0.36	-0.37	-0.27	-0.46	-0.32	-0.42	-0.21		-0.52	-0.62	-0.31	0.07	-0.14	0.78	0.49	-0.14	-0.73	-0.36	-0.22	-0.02	-0.25	-0.37	0.22
Total Liab	0.62	-0.05	0.16	0.14	0.62	0.46	0.6	0.07	-0.37	0.82	-0.52		0.59	0.73	-0.72	0.38	-0.24	-0.01	0.53	0.25	0.33	0.49	0.31	-0.29	0.68	0.53
Total Current Assets	0.99	-0.02	0.18	-0.19	0.87	0.43	0.96	-0.12	0.0	0.43	-0.62	0.59		0.54	0.07	0.32	-0.19	-0.27	0.52	0.41	0.54	0.57	-0.03	0.03	0.38	0.13
Short Long Term Debt Total	0.6	-0.02	0.32	-0.05	0.66	0.62	0.65	-0.08	-0.33	0.48	-0.31	0.73	0.54		-0.35	0.62	-0.03	0.23	0.57	0.17	0.36	0.49	0.38	-0.33	0.41	0.43
Total Stockholder Equity	0.04	0.17	0.02	-0.35	-0.05	-0.11	0.05	-0.11	0.61	-0.68	0.07	-0.72	0.07	-0.35		-0.06	0.03	-0.17	-0.22	0.15	0.04	-0.13	-0.33	0.45	-0.6	-0.49
Property Plant And Equipment Net	0.46	0.33	0.13	-0.44	0.31	0.97	0.34	0.36	0.04	0.27	-0.14	0.38	0.32	0.62	-0.06		-0.14	0.53	0.15	0.13	0.06	0.16	0.67	-0.02	0.13	0.63
Retained Earnings	-0.22	-0.43	-0.56	-0.45	0.15	-0.25	0.02	-0.62	-0.7	0.11	0.78	-0.24	-0.19	-0.03	0.03	-0.14		0.25	0.07	-0.79	-0.07	-0.04	-0.3	-0.57	-0.05	0.25
Non Currrent Assets Other	-0.16	0.1	-0.2	-0.31	-0.12	0.47	-0.18	0.36	-0.25	0.11	0.49	-0.01	-0.27	0.23	-0.17	0.53	0.25		0.1	-0.33	-0.32	0.07	0.76	-0.18	0.02	0.51
Common Stock Total Equity	0.5	-0.45	-0.1	-0.3	0.69	0.18	0.62	-0.13	-0.33	0.55	-0.14	0.53	0.52	0.57	-0.22	0.15	0.07	0.1		0.08	0.07	0.98	0.16	-0.44	0.48	0.46
Other Stockholder Equity	0.41	0.3	0.35	0.32	0.15	0.22	0.26	0.39	0.65	0.02	-0.73	0.25	0.41	0.17	0.15	0.13	-0.79	-0.33	0.08		0.01	0.18	0.03	0.47	0.05	-0.29
Short Term Debt	0.51	0.2	0.66	0.24	0.38	0.11	0.54	-0.36	0.02	-0.08	-0.36	0.33	0.54	0.36	0.04	0.06	-0.07	-0.32	0.07	0.01		0.06	-0.16	0.09	-0.15	-0.17
Common Stock	0.56	-0.39	-0.08	-0.31	0.66	0.22	0.63	-0.02	-0.2	0.49	-0.22	0.49	0.57	0.49	-0.13	0.16	-0.04	0.07	0.98	0.18	0.06		0.16	-0.36	0.45	0.4
Accounts Payable	0.09	0.13	0.15	-0.1	-0.05	0.67	-0.04	0.54	-0.04	0.19	-0.02	0.31	-0.03	0.38	-0.33	0.67	-0.3	0.76	0.16	0.03	-0.16	0.16		0.08	0.22	0.5
Short Term Investments	0.02	0.52	0.42	0.15	-0.27	0.01	-0.14	0.22	0.72	-0.51	-0.25	-0.29	0.03	-0.33	0.45	-0.02	-0.57	-0.18	-0.44	0.47	0.09	-0.36	0.08		-0.31	-0.42
Other Assets	0.38	-0.29	-0.27	-0.08	0.56	0.2	0.39	0.03	-0.5	0.78	-0.37	0.68	0.38	0.41	-0.6	0.13	-0.05	0.02	0.48	0.05	-0.15	0.45	0.22	-0.31		0.41
Other Liab	0.23	-0.13	-0.35	-0.58	0.34	0.6	0.24	0.11	-0.49	0.69	0.22	0.53	0.13	0.43	-0.49	0.63	0.25	0.51	0.46	-0.29	-0.17	0.4	0.5	-0.42	0.41

Click cells to compare fundamentals

Protalix Biotherapeutics Account Relationship Matchups

Protalix Biotherapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	45.4M	67.9M	73.7M	55.8M	84.4M	51.0M
Other Current Liab	11.9M	13.9M	16.4M	12.3M	16.7M	17.5M
Total Current Liabilities	40.2M	86.5M	33.2M	32.4M	45.5M	47.8M
Net Debt	43.1M	46.1M	(5.5M)	16.4M	2.6M	2.8M
Cash	17.8M	18.3M	39.0M	17.1M	23.6M	31.8M
Non Current Assets Total	12.9M	12.2M	12.0M	10.9M	14.5M	9.6M
Cash And Short Term Investments	17.8M	38.5M	39.0M	22.2M	44.6M	33.7M
Net Receivables	4.7M	2M	3.4M	4.6M	5.3M	3.1M
Common Stock Shares Outstanding	14.8M	29.1M	44.1M	48.5M	82.4M	86.5M
Liabilities And Stockholders Equity	45.4M	67.9M	73.7M	55.8M	84.4M	51.0M
Non Current Liabilities Total	75.5M	8.5M	46.5M	34.0M	5.3M	5.1M
Other Current Assets	698K	2.1M	1.3M	536K	1.1M	1.6M
Total Liab	115.7M	95.0M	79.7M	66.4M	50.9M	56.1M
Total Current Assets	32.5M	55.7M	61.7M	44.9M	69.9M	42.5M
Short Long Term Debt Total	60.9M	64.4M	33.5M	33.5M	26.3M	51.0M
Total Stockholder Equity	(70.3M)	(27.0M)	(6.0M)	(10.6M)	33.6M	35.2M
Property Plant And Equipment Net	11.0M	10.4M	9.9M	9.6M	10.9M	10.5M
Retained Earnings	(340.8M)	(347.4M)	(374.9M)	(389.9M)	(381.5M)	(362.5M)
Non Currrent Assets Other	2.0M	1.8M	2.1M	1.3M	528.0K	501.6K
Common Stock Total Equity	144K	148K	15K	35K	40.3K	62.7K
Other Stockholder Equity	270.5M	320.3M	368.9M	379.2M	415.0M	435.8M
Short Term Debt	5.4M	59.9M	1.2M	1.1M	21.7M	16.5M
Common Stock	15K	35K	46K	54K	73K	62.8K
Accounts Payable	6.5M	7.2M	7.0M	5.9M	4.3M	4.3M
Short Term Investments	26K	20.3M	39.0M	5.1M	20.9M	22.0M
Other Assets	2.0M	7.4K	2.1M	1.3M	1.0	0.95
Other Liab	20.1M	4.0M	14.3M	1.6M	1.5M	1.4M
Property Plant Equipment	5.3M	10.4M	9.9M	9.6M	8.7M	8.1M
Current Deferred Revenue	16.3M	5.4M	8.6M	13.2M	2.9M	2.7M
Inventory	8.2M	13.1M	18.0M	16.8M	19.0M	9.6M
Net Tangible Assets	(70.3M)	(27.0M)	(6.0M)	(10.6M)	(9.6M)	(10.1M)
Long Term Debt	51.0M	51K	27.9M	28.2M	25.4M	28.8M
Capital Surpluse	270.5M	320.3M	368.9M	379.2M	436.0M	272.0M
Non Current Liabilities Other	5.1M	5.3M	75.5M	51K	45.9K	43.6K
Long Term Debt Total	51.5M	51K	27.9M	28.2M	25.4M	28.3M
Net Invested Capital	(15.1M)	31.5M	21.9M	17.5M	53.8M	56.5M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protalix Biotherapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Protalix Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protalix Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protalix Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protalix Biotherapeutics Stock:

How To Invest In Protalix

Details

Is Protalix Stock a good investment?

Details

What is Protalix Biotherapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Protalix Stock analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

	Stocks Directory Find actively traded stocks across global markets
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings

Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.39)

Earnings Share

0.09

Revenue Per Share

0.97

Quarterly Revenue Growth

0.217

Return On Assets

0.0933

The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protalix Cost Of Revenue vs Ebitda Analysis

Cost Of Revenue vs Ebitda

Cost Of Revenue vs Ebitda Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Ebitda

Protalix Biotherapeutics fundamental ratios Correlations

Protalix Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protalix Biotherapeutics fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Protalix Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Common Stock	+ 0.98	Common Stock Total Equity
Property Plant And Equipment Net	+ 0.97	Non Current Assets Total
Total Current Assets	+ 0.96	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.95	Total Assets
Cash And Short Term Investments	+ 0.95	Cash

Other Stockholder Equity	- 0.79	Retained Earnings
Other Stockholder Equity	- 0.73	Other Current Assets
Total Stockholder Equity	- 0.72	Total Liab
Retained Earnings	- 0.7	Common Stock Shares Outstanding
Total Stockholder Equity	- 0.68	Non Current Liabilities Total
Total Current Assets	- 0.62	Other Current Assets